FamiCord Group, the largest cord blood bank in Europe, and CelluGen Biotech, a biotech company headquartered in Gurgaon, India, have signed a letter of intent (LOI) to cooperate across a range of business activities. Dated April 25, 2019, the specifics of the LOI state that the companies will pursue cooperation within the “field of family cord blood banking of stem cells and the use of stem cells in experimental and standard therapies.” The companies may jointly develop ATMPs and drugs. [Read more…]
Stem Cell News
BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.
As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.
Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.
ExCellThera’s Cell Expansion Technology, ECT-001, Receives FDA RMAT Designation
MONTREAL, April 23, 2019 — ExCellThera Inc., an advanced clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that the U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to its lead technology, ECT-001, in the treatment of hematologic malignancies. The RMAT designation is based on strong data from Phase I/II clinical trials using ECT-001 to expand stem and immune cells for the treatment of blood cancers. [Read more…]
Talaris Therapeutics Receives RMAT, Raises $100M, Announces Promising Phase II Data for Kidney Transplant
Talaris Therapeutics’ RMAT and Promising Phase 2 Data of Cell Therapy for Living Donor Kidney Transplant Recipients
BOSTON & LOUISVILLE, Ky.–Apr 18, 2019–Talaris Therapeutics, Inc., formerly Regenerex, a privately held biotechnology company developing transformative cell therapies that have the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients, today announced full results of its Phase 2 trial of FCR001 in living donor kidney transplant (LDKT) recipients. The therapy’s strong durability of benefit and safety profile support the initiation of a Phase 3 clinical trial in LDKT later this year.
Dr Professor Eckhard Alt from Germany to Lecture at AAOSCP’s May 2019 Workshop
Dr. Prof. Alt is a Leading Authority on Stem Cells, Electrophysiology, and Interventional Cardiology.
On May 3-5, 2019, the American Academy of Stem Cell Physicians (AAOSCP) will host a Scientific Congress and Workshop, featuring Basic Science to Clinical Practice. The AAOSCP is honored to announce that the event will feature renowned lecturer Eckhard U. Alt, MD, PhD, Professor of Medicine at Technische Universität in Munich, Professor at Tulane University in New Orleans and Professor at University of Texas MD Anderson Cancer Center in Houston. Dr. Prof. Alt is a leading global authority on Stem Cells, Electrophysiology, and Interventional Cardiology, holding more than 650 patents on these subjects worldwide. [Read more…]
Demand Peaks for AAOSCP’s May 2019 “Basic Science to Clinical Practice” Stem Cell Workshop
Never before has a workshop featured BM, SVF, UCB, Peptides, Cytokines and Exosomes under the same roof.
The American Academy of Stem Cell Physicians (AAOSCP) is hosting a May 2019 conference that is filling up fast. With limited space available, medical practitioners who are seeking to learn skills and techniques for integrating regenerative medicine (RM) into their practice are encouraged to register immediately. [Read more…]
- « Previous Page
- 1
- …
- 113
- 114
- 115
- 116
- 117
- …
- 145
- Next Page »